Clover Health targets a meaningful earnings opportunity through 2028 and expects full-year 2026 Adjusted SG&A ratio improvement of 100–150 basis points year over year. It reported ~159k members at the end of 3Q26 and offered no formal 2027 or 2028 guidance.
CLOV · Clover Health Investments, Corp.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $3.77
- Open
- $4.24
- Day range
- $3.76–4.30
- 52-week closing range
- $1.70–5.41
- Average volume, 30 days
- 4.9M
- Short interest
- 23.0M · 4.3% of shares · 6.7 days
- Short volume, last session
- 51%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 6
- Price history
- Jun 2020 to Nov 2026
Up next
Latest documents
Clover Health expects another strong year of membership growth in 2027, with cohort maturation and Clover Assistant coverage supporting substantial margin expansion; year-to-date adjusted EBITDA reached $97 million and net income $62 million.
Clover Health Investments, Corp. reported nine-month revenue of $2,251.7 million, up 57%, and net income of $61.8 million versus prior-year losses. Adjusted EBITDA rose to $97.2 million, while cash, cash equivalents, and investments totaled $512.6 million at September 30, 2026.
Clover Health Investments, Corp. reported third quarter 2026 GAAP net income of $6 million and raised full-year guidance to $2.97 billion - $3.00 billion revenue, $25 million - $35 million net income and $75 million - $85 million Adjusted EBITDA.
CMS awarded Clover Health Investments, Corp. PPO plans 5 Stars and its HMO plan 4.5 Stars for 2027, affecting payment year 2028. CMS excluded 20 measures under appealed court decision; including them would have given the PPO plans 4.5 Stars.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Clover Health reported 48% Medicare Advantage membership growth alongside $28M Q2 GAAP net income, raised full-year 2026 guidance across all metrics citing strong cohort maturation, and signaled increasing confidence in 2027 supported by a 4.5-star payment year.
- + Raised full-year 2026 guidance across all metrics including revenue, gross profit, Adjusted EBITDA, GAAP net income and membership
- + Medicare Advantage membership grew 48% year-over-year in Q2 with $743M revenue up 56%
- + Achieved $28M Q2 GAAP net income and $41M Adjusted EBITDA, both materially improved year-over-year
- + 4.5-star payment year confirmed following court ruling, providing additional flexibility for 2027 bids
- + Adjusted SG&A improved ~220 bps as a percent of revenue, demonstrating operating leverage at scale
- − CMS has appealed the district court ruling on star rating recalculation, creating uncertainty around the 4.5-star outcome
- − Company expects a typical seasonal Q4 adjusted EBITDA loss after positive Q3
- − Outpatient utilization trends remain elevated from prior years despite moderation from March peak
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Net income non-GAAP | $40.35M | Three Months Ended June 30, 2026 filing | — |
| Insurance Benefits Expense Ratio | 87.6% | Three Months Ended June 30, 2026 filing | — |
| Net medical claims incurred per member | $1,254 | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $81.2M | Six Months Ended June 30, 2026 | — |
| Adjusted Net income (non-GAAP) non-GAAP | $80.09M | Six Months Ended June 30, 2026 | — |
| Adjusted SG&A (non-GAAP) non-GAAP | $231.37M | Six Months Ended June 30, 2026 | — |
| Adjusted SG&A as a % of Total revenues non-GAAP | 15.5% | Six Months Ended June 30, 2026 | — |
| Average Medicare Advantage membership | 155,723 | Six Months Ended June 30, 2026 | — |
| Consolidated Gross profit (non-GAAP) non-GAAP | $312.54M | Six Months Ended June 30, 2026 | — |
| Insurance Benefits Expense (non-GAAP) non-GAAP | 1.29B | Six Months Ended June 30, 2026 | — |
| Insurance BER non-GAAP | 87.1% | Six Months Ended June 30, 2026 | — |
| Insurance Segment gross profit | $256.53M | Six Months Ended June 30, 2026 | — |
| Lives under Clover Management - Insurance members | 157,309 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLOV
this stock
Clover Health Investments, Corp.
|
$2.02B | +60.4% | +40.3% | — | 4.3% |
|
UNH
Unitedhealth Group Inc
|
$296.12B | +0.1% | +11.8% | 18.9 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$102.41B | +0.9% | +7.8% | 9.3 | 1.4% |
|
ELV
Elevance Health, Inc.
|
$84.30B | +11.3% | +12.5% | 16.6 | 2.1% |
|
CI
Cigna Group
|
$71.95B | -0.8% | +11.2% | 12.1 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 32
Clover Health targets a meaningful earnings opportunity through 2028 and expects full-year 2026 Adjusted SG&A ratio improvement of 100–150 basis points year over year. It reported ~159k members at the end of 3Q26 and offered no formal 2027 or 2028 guidance.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLOV | -22.8% | -20.3% | -3.8% | -15.5% | +60.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -17.3% | -14.0% | +1.8% | -10.2% | +55.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.